Brand name
Azactam, the original
We didn’t find a savings card or cash price from Azactam’s maker. Ask the pharmacy for Azactam’s cash price. With insurance, ask what your plan charges.
Generic name: aztreonam
Used for: Urinary tract infections · Lung and airway infections · Blood infections (septicemia) · Skin infections · Abdominal infections · Gynecologic infections · Infections treated along with surgery (such as abscesses) · 6 more
Ask for the cash price
Generic aztreonam
No pharmacy we check posts a price for it.
A regular generic has the same active ingredient as Azactam, and the FDA requires it to work the same way.
Azactam, the original
We didn’t find a savings card or cash price from Azactam’s maker. Ask the pharmacy for Azactam’s cash price. With insurance, ask what your plan charges.
There isn’t one.
Same active ingredient as Azactam. Fillers and dyes can differ.
One company sells a generic of Azactam that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
It’s mostly filled by specialty pharmacies. Your prescriber’s office or insurer can tell you which one to use.
1 g
| Package | NDC |
|---|---|
| Carton of 10 | 0409-0829-01 |
2 g
| Package | NDC |
|---|---|
| Carton of 10 | 0409-0830-01 |
Inactive ingredients: arginine
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
“Before you fill my Azactam, can you tell me what I’d pay for the brand and for a generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca*, Citrobacter species*, and Serratia marcescens*.
Lower Respiratory Tract Infections, including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens*.
Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis*, Serratia marcescens*, and Enterobacter species.
Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*.
Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae*, Pseudomonas aeruginosa, Citrobacter species* including C. freundii*, and Serratia species* including S. marcescens*.
Gynecologic Infections, including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae*, Enterobacter species* including E. cloacae*, and Proteus mirabilis*.
AZACTAM is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. AZACTAM is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery.
Concurrent Therapy
Concurrent initial therapy with other antimicrobial agents and AZACTAM is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to Gram-positive aerobic pathogens. If anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with AZACTAM (see DOSAGE AND ADMINISTRATION ). Certain antibiotics (eg, cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some Gram-negative aerobes such as Enterobacter and Pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. These in vitro findings suggest that such beta-lactamase-inducing antibiotics not be used concurrently with aztreonam. Following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued.
Source: the FDA label for Azactam (E.R. Squibb & Sons, L.L.C.), December 15, 2025. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/azactam/